252 related articles for article (PubMed ID: 19393583)
1. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
Celis JE; Cabezón T; Moreira JM; Gromov P; Gromova I; Timmermans-Wielenga V; Iwase T; Akiyama F; Honma N; Rank F
Mol Oncol; 2009 Jun; 3(3):220-37. PubMed ID: 19393583
[TBL] [Abstract][Full Text] [Related]
2. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
Celis JE; Gromov P; Cabezón T; Moreira JM; Friis E; Jirström K; Llombart-Bosch A; Timmermans-Wielenga V; Rank F; Gromova I
Mol Cell Proteomics; 2008 Oct; 7(10):1795-809. PubMed ID: 18632593
[TBL] [Abstract][Full Text] [Related]
3. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
[TBL] [Abstract][Full Text] [Related]
4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
Celis JE; Gromova I; Gromov P; Moreira JM; Cabezón T; Friis E; Rank F
FEBS Lett; 2006 May; 580(12):2935-44. PubMed ID: 16631754
[TBL] [Abstract][Full Text] [Related]
6. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
Celis JE; Moreira JM; Gromova I; Cabezón T; Gromov P; Shen T; Timmermans V; Rank F
Mol Oncol; 2007 Jun; 1(1):97-119. PubMed ID: 19383289
[TBL] [Abstract][Full Text] [Related]
7. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.
Celis JE; Gromov P; Moreira JM; Cabezón T; Friis E; Vejborg IM; Proess G; Rank F; Gromova I
Mol Cell Proteomics; 2006 Mar; 5(3):462-83. PubMed ID: 16316978
[TBL] [Abstract][Full Text] [Related]
8. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
Tramm T; Kim JY; Tavassoli FA
Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
[TBL] [Abstract][Full Text] [Related]
9. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
11. α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
Nakamura H; Kukita Y; Kunimasa K; Kittaka N; Kusama H; Nakayama T; Tamaki Y; Sugiura R; Yasuda H; Hashimoto M; Yamamoto T; Imamura F; Nakatsuka SI
Hum Pathol; 2021 Oct; 116():39-48. PubMed ID: 34314764
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
13. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions.
Chantzi NI; Palaiologou M; Stylianidou A; Goutas N; Vassilaros S; Kourea HP; Dhimolea E; Mitsiou DJ; Tiniakos DG; Alexis MN
J Cancer Res Clin Oncol; 2014 Jun; 140(6):1057-66. PubMed ID: 24671226
[TBL] [Abstract][Full Text] [Related]
15. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
17. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast.
D'Arcy C; Quinn C
J Clin Pathol; 2019 Jan; 72(1):1-6. PubMed ID: 30409840
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
19. Non-operative breast pathology: apocrine lesions.
Wells CA; El-Ayat GA
J Clin Pathol; 2007 Dec; 60(12):1313-20. PubMed ID: 18042688
[TBL] [Abstract][Full Text] [Related]
20. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
Elayat G; Selim AG; Wells CA
Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
